A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-08

Study Completion Date

2007-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908

Advanced Solid Tumor

RECRUITING PHASE1

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

NCT02385669

Melanoma

TERMINATED PHASE1/PHASE2

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

NCT05695898

Metastatic Melanoma Advanced Melanoma

TERMINATED PHASE1

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

NCT03526185

Metastatic Melanoma

TERMINATED EARLY_PHASE1

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

NCT04458922

Central Chondrosarcoma, Grade 2 Central Chondrosarcoma, Grade 3 Dedifferentiated Chondrosarcoma +3 more

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 750-900 people in the United States each year develop synovial sarcoma, a rare form of cancer of connective tissue. This tumor frequently metastasizes to other parts of the body such as the lungs. Chemotherapy can sometimes decrease the size of the recurrent tumors, but these results are usually only temporary, and the tumors grow again.

We are trying to exploit some of the proteins made by synovial sarcoma (cancer-germ cell or cancer-testis antigens) as targets for the immune system. Specifically, we are investigating if immune-based therapy with anti-CTLA-4 antibody once every 3 weeks for three treatments will activate the immune system enough to attack recurrent synovial sarcoma. In this study the tumor itself serves as the "vaccine" or source of protein, as we try to activate tumor-fighting T cells with the anti-CTLA-4.

Anti-CTLA-4 takes the brakes off the immune system to allow otherwise hidden immune responses to become more active. In so doing, there could be other side effects, such as immune system attacks against the normal organs of the body. We will follow both the anti-tumor immune responses with frequent blood tests and follow and treat side effects people develop on this study to determine if anti-CTLA-4 is worth pursuing in a larger number of patients with synovial sarcoma or other sarcomas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Synovial Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ipilimumab

Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.

Group Type EXPERIMENTAL

ipilimumab

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ipilimumab

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-CTLA-4 monoclonal antibody monoclonal antibody MDX-010 Yervoy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically documented synovial sarcoma.
* Patients with metastatic disease or locally recurrent disease who have failed or refused standard treatment. The disease must be measurable by RECIST.
* Expected survival of at least 6 months.
* Weight at least 35 kg.
* ECOG performance scale 0-2.
* At least 3 weeks since major surgery, and at least 3 weeks since completing radiation therapy or chemotherapy (6 weeks for patients receiving mitomycin C).
* Resolution of toxicity from previous treatment to NCI-CTC grade 1 or less before treatment.
* Adequate bone marrow, renal and hepatic function.
* Able and willing to give valid written informed consent.

Exclusion Criteria

* Clinically significant heart disease (NYHA Class III or IV).
* Other serious illnesses, e.g. serious infections requiring antibiotics or bleeding disorders.
* History of autoimmune disease.
* Serious intercurrent illness, requiring hospitalization.
* Patients with a second cancer diagnosis in the last five years, except for basal cell carcinoma, completely resected, or cervical carcinoma in situ (CIN), completely resected.
* Known HIV positivity.
* Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
* Chronic use of immunosuppressive drugs such as systemic corticosteroids.
* Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
* Lack of availability for immunological and clinical follow-up assessments.
* Participation in any other clinical trial involving another investigational agent within 3 weeks prior to enrollment.
* Pregnancy or breast feeding.
* Refusal or inability to use effective means of contraception (all men, and women with childbearing potential).

Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No